Bactericidal synergy of lysostaphin in combination with antimicrobial peptides
Bactericidal synergy of lysostaphin in combination with antimicrobial peptides
复制标题
DOI：
10.1007/s10096-011-1188-z
复制
发表时间：
2011-08-01
影响因子：
4.5
通讯作者：
Coote, P. J.
中科院分区：
文献类型：
--
作者：
Desbois, A. P.;Coote, P. J.
耐药葡萄球菌构成了一个严重的问题，迫切需要发现新的治疗药物。人们对使用溶葡萄球菌酶(一种特殊的抗葡萄球菌酶)治疗由这些重要病原体引起的感染的兴趣重新抬头。然而，细菌对溶葡萄球菌酶的耐药性是一个问题，但联合治疗的使用可能会克服这个问题。在这项研究中，通过使用悬浮培养的活菌计数，溶葡萄球菌酶与各种常规抗菌肽、抗菌蛋白牛乳铁蛋白、一种抗生素(乳链菌素)和某些临床使用的脂肽(粘菌素、达托霉素和多粘菌素B)一起显示出协同杀菌作用。协同作用的组合具有临床重要性，因为这些组合减少了有效治疗所需化合物的剂量，并降低了选择耐药性的机会。溶葡萄球菌酶与多肽的结合使用可能代表了解决耐药葡萄球菌的一种新途径。
Drug-resistant staphylococci constitute a serious problem that urgently requires the discovery of new therapeutic agents. There has been a resurgence in interest in using lysostaphin (a specific anti-staphylococcal enzyme) as a treatment for infections caused by these important pathogens. However, bacterial resistance to lysostaphin is a problem, but the use of a combination treatment may surmount this issue. In this present study, using viable counts from suspension incubations, lysostaphin is shown to be synergistically bactericidal in combination with various conventional antimicrobial peptides, the antimicrobial protein bovine lactoferrin, a lantibiotic (nisin), and certain lipopeptides used clinically (colistin, daptomycin and polymyxin B). Combinations that act in synergy are of clinical importance as these reduce the doses of the compounds needed for effective treatments and decrease the chances of resistance being selected. The use of lysostaphin in combination with a peptide may represent a new avenue in tackling drug-resistant staphylococci.